Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
28.78
+2.59 (9.89%)
At close: Apr 14, 2026, 4:00 PM EDT
28.65
-0.13 (-0.45%)
After-hours: Apr 14, 2026, 5:48 PM EDT
Sutro Biopharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover Sutro Biopharma stock have a consensus rating of "Buy" and an average price target of $26.38, which forecasts a -8.34% decrease in the stock price over the next year. The lowest target is $8.00 and the highest is $55.
Price Target: $26.38 (-8.34%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sutro Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 2 | 2 |
| Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Hold | 5 | 6 | 5 | 5 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Strong Buy Maintains $51 → $55 | Strong Buy | Maintains | $51 → $55 | +91.10% | Mar 25, 2026 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $8 → $27 | Hold → Buy | Upgrades | $8 → $27 | -6.18% | Mar 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $10 → $28 | Hold → Strong Buy | Upgrades | $10 → $28 | -2.71% | Mar 24, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $23 | Hold → Buy | Upgrades | $23 | -20.08% | Jan 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $2 → $10 | Hold | Maintains | $2 → $10 | -65.25% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
38.19M
from 102.48M
Decreased by -62.74%
Revenue Next Year
35.90M
from 38.19M
Decreased by -5.98%
EPS This Year
-8.57
from -22.49
EPS Next Year
-8.96
from -8.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 63.0M | 72.5M | |||
| Avg | 38.2M | 35.9M | |||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -38.5% | 89.7% | |||
| Avg | -62.7% | -6.0% | |||
| Low | -90.4% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.10 | -4.79 | |||
| Avg | -8.57 | -8.96 | |||
| Low | -11.97 | -13.66 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.